

► Faculty ◀

Jeff DuBois, Ph.D.
Vice President Medical & Scientific Affairs
Nova Biomedical, Waltham, MA

Dr. DuBois has been with Nova Biomedical since 1999. Prior to joining Nova, he was on the faculty of the School of Medicine, Case Western Reserve University and served as Executive Director of Laboratory Services at University Hospitals Health System (UHHS), Cleveland, OH. At UHHS, he established a system-wide strategy for lab consolidation, standardization, and integration. He also implemented a POC Process Improvement Initiative involving Nova's Analyzers and Data Management System for remote connectivity of analyzers located in the ER, ICUs, and ORs to the laboratory. He represented UHHS and Nova Biomedical on the NCCLS Automation Area Committee, initiated the NCCLS Committee on Point-of-Care Connectivity for which he served as Chairperson, and founded the Area Committee for POCT for which he served as its Chair for two years. Dr. DuBois is well published and a frequent speaker on connectivity, lab automation, lab consolidation, and point-of-care testing. He is a fellow of the Academy of Clinical Biochemists, a member of the American Association of Clinical Chemistry, American Diabetes Association, The Endocrinology Society, and the European Association for the Study of Diabetes.

William Clarke Ph.D.
Director of TDM and Toxicology
Director POC Dept of Pathology
Johns Hopkins School of Medicine

William Clarke, PhD, MBA, DABCC is an Assistant Professor in the Department of Pathology at the Johns Hopkins School of Medicine, as well as the director of both Point-of-Care Testing and TDM/Toxicology at the Johns Hopkins Hospital. He received his doctorate in Analytical Chemistry from the University of Nebraska at Lincoln in 2000, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine, ending in 2002. Research interests include clinical mass spectrometry, pharmacoproteomics, evaluation of point-of-care testing technology, as well as development and evaluation of analytical methods for TDM and toxicology. He is an active member of the AACC, both in the local section and in the TDM/Tox division.

► Seminar Program ◀

9:00 a.m. - 9:45 a.m. Glucose/Ketone Alterations in Inpatient Settings: Overview of Causes, Consequences and Control.

William Clarke, Ph.D.

9:45 a.m. - 10:15 a.m. Glucose Biosensor Eliminates Errors from Hematocrit, Maltose, and Other Interferences

Jeff Dubois, Ph.D.

10:15 a.m. - 10:45 a.m. FDA, SCCM, AACE: Current Glucose Meters Are Inadequate for Glucose Control in the ICU

Jeff Dubois, Ph.D.

11:00 a.m. - 11:45 a.m. New Biosensor Technology for Hospital Bedside Testing

Ron Newby,
Director of Marketing

11:45 a.m. Lunch

► Continuing Education Information ◀

Nova Biomedical is approved as a Provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.[®] program. This seminar provides 1.5 contact hours for P.A.C.E.[®] continuing education credits.

► Seminar Dates and Locations ◀

Wednesday, November 10, 2010
Renaissance Marriott Chicago
1 West Wacker Drive
Chicago, IL 60601
Phone: 1-312-372-7200

Thursday, November 11, 2010
Columbus Marriott Northwest
5605 Blazer Pkwy
Dublin, Ohio 43017
Phone: 1-614-791-1000

Tuesday, November 16, 2010
Boston Marriott Newton
2345 Commonwealth Avenue
Newton, MA 02466
Phone: 1-617-969-1000

Thursday, November 18, 2010
Miami Marriott Biscayne Bay
1633 North Bayshore Drive
Miami, FL 33132
Phone: 1-305-374-3900

To register, mail or fax this postage-paid card.
You may also register on our web site at
www.novabiomedical.com/gluseminar
or by calling 800-458-5813 or 781-894-0800
and asking for Jennifer Cole. ext. 424 jcole@novabio.com
You will receive an email message confirming your registration.

P.A.C.E.[®] is a registered trademark of the American Society of Clinical Laboratory Science.

► Seminar Registration Form ◀

**Bedside Glucose Testing:
Delivering a New Standard of Care**

Full Name: _____

Title: _____

Department: _____

Organization: _____

Street Address: _____

City: _____

State: _____ Zip Code: _____

Phone: _____

Fax: _____

E-mail: _____

► Register Now! Seating Is Limited ◀

PLEASE CHECK ONE:



- Wednesday, November 10th – Chicago, IL
- Thursday, November 11th – Columbus, OH
- Tuesday, November 16th – Boston, MA
- Thursday, November 18th – Miami, FL

To register, mail or fax this postage-paid card.
You may also register on our web site at
www.novabiomedical.com/gluseminar
or by calling 800-458-5813 or 781-894-0800
and asking for Jennifer Cole. ext. 424 jcole@novabio.com
You will receive an email message confirming your registration.

nova
biomedical

200 Prospect Street, Waltham, MA 02454-9141
Tel: 800-458-5813 781-894-0800
Fax: 781-894-5915
Email: info@novabio.com
www.novabiomedical.com

NO POSTAGE
NECESSARY
IF MAILED
IN THE
UNITED STATES



BUSINESS REPLY MAIL
FIRST-CLASS MAIL PERMIT NO. 47966 BOSTON MA

POSTAGE WILL BE PAID BY ADDRESSEE

**NOVA BIOMEDICAL
PO BOX 9141
WALTHAM MA 02454-9729**



PRESORTED
STANDARD RATE
U.S. POSTAGE PAID
Boston, MA
Permit No. 54514

nova
biomedical
Nova Biomedical
200 Prospect Street
Waltham, MA 02454
U.S.A.

▶ You Are Invited to a Nova Biomedical Educational Seminar ◀

▶ You Are Invited to a Nova Biomedical Educational Seminar ◀

Bedside Glucose Testing: Delivering a New Standard of Care

New Technology for Improved Accuracy and Patient Safety

Wednesday, November 10th – Chicago, IL

Thursday, November 11th – Columbus, OH

Tuesday, November 16th – Boston, MA

Thursday, November 18th – Miami, FL

The introduction of glycemic control protocols for critically ill patients has been associated with improved clinical outcomes such as reductions in length of stay, morbidity, risk of sepsis, renal failure and mortality. Frequent, fast, and accurate bedside glucose testing is imperative to rapidly achieve the glucose target levels, and improved clinical outcomes that these protocols have shown. The fast turnaround time and ease of operation of home use blood glucose monitors has led to their widespread use in glycemic control protocols in hospitals. However these monitors were originally developed for home use by healthy people with diabetes and their inaccuracy and error rate for critical care patients is a growing concern.

The FDA, Society of Critical Care Medicine (SCCM), American Association of Clinical Endocrinologists (AACE) and others are calling for improved accuracy of glucose monitors for use on hospitalized patients. Published reports and clinical experience indicate that current glucose monitors can cause erroneous glucose results, inappropriate insulin doses and adverse events related to glycemic control. Whereas hospitalized patients are sicker (such as those in the ICU) than ambulatory patients, any inaccuracies of glucose monitors pose risks of greater magnitude than would be encountered in the ambulatory population. As adverse incidents and even deaths are still being reported, the inaccuracy of current glucose meters used in the hospital has become a concern for the FDA and others including ADA, SCCM and AACE.

This educational seminar will discuss the following topics

- Causes and consequences of glucose alterations in hospitalized patients
- Improved outcomes associated with glycemic control
- Issues confounding the delivery of accurate, reliable bedside glucose testing
- A new technology that meets the demand for accurate, safe bedside glucose testing

The patented, interference-free StatStrip Hospital Glucose Monitoring System will be described. Data will be summarized from over 40 studies conducted throughout the world characterizing the accuracy of this new technology at wide ranges of glucose; with common interferences such as hematocrit, maltose, and oxygen.

▶ This Seminar will be Beneficial for: ◀

- POC Supervisors
- Laboratory Managers
- Nursing Directors
- Diabetes Educators

nova
biomedical